Fast IHC Advantage Novodiax offers ihcDirect rapid immunohistochemistry assays delivering results in about 10 minutes and significant FFPE workflow time savings, presenting a compelling value proposition for hospitals and reference labs seeking faster diagnostics and increased throughput.

IVD Ready Portfolio With in vitro diagnostic use approval for ihcDirect kits like CK19 and CK20, there is a clear pathway to sell to clinical labs, pathology groups, and distributors seeking certified, room-temperature, user-friendly immunoassay solutions.

CoDx Collaboration Novodiax emphasizes companion diagnostics development and research collaboration through ihcPrime and Q-Stain products, enabling strategic partnerships with pharma, diagnostics developers, and biotech firms pursuing CDx programs.

Low Footprint The assays require minimal lab space and no specialized equipment, facilitating sales to small or resource-limited labs, ambulatory centers, or startups looking to modernize pathology workflows without heavy capital expenditure.

Growth Signals Revenue range indicates a small to mid-stage biotech with recent product launches and awards, suggesting upsell opportunities around expanded kit lines, custom services, and regional expansion through distributors to accelerate market adoption.